Vivos Therapeutics Expands Patent Protection for Sleep Apnea Device Technology
Event summary
- Vivos Therapeutics received a new US patent (No. 12,697,190) broadening protection for its Vivos CARE oral medical device technology on August 5, 2026.
- The new patent complements the previously issued US Patent No. 12,048,608, strengthening intellectual property around Vivos' proprietary line of oral medical devices.
- Vivos CARE devices have received unprecedented FDA 510K clearances for treating severe OSA in adults and moderate to severe OSA in children.
- Studies show approximately 80% of patients treated with Vivos CARE devices achieve significant reductions or complete resolution of OSA symptoms.
The big picture
Vivos Therapeutics' expanded patent protection comes at a critical time as the market for safe and effective alternatives to CPAP machines grows. With over one billion people globally suffering from sleep apnea, and 80% remaining undiagnosed, Vivos' technology addresses a significant unmet need. The company's FDA clearances and strong patient outcomes position it as a leader in non-invasive treatments for obstructive sleep apnea.
What we're watching
- Competitive Barriers
- How the expanded patent protection will affect competitors' ability to design around Vivos' mandibular advancement technology.
- Market Adoption
- Whether the strengthened intellectual property position will accelerate the commercialization of Vivos CARE devices in the growing sleep apnea market.
- Regulatory Dynamics
- The pace at which FDA-mandated CPAP recalls and increased mortality risks associated with CPAP will drive demand for alternative treatments like Vivos CARE devices.